Old phenothiazine with a genuine low-dose mitochondrial story; speculative cognitive signal but solid bench utility
Look, methylene blue is a weird one. It’s the oldest synthetic pharmaceutical compound still in active use, first synthesized in 1876, and its continued relevance is more interesting than its history suggests. The thing that matters for modern research isn’t the methemoglobinemia indication or the old antimalarial work. It’s the low-dose electron-cycling story, and thats worth taking seriously.
Here’s the mechanism as best we understand it: at low doses, methylene blue acts as an electron donor to Complex III of the mitochondrial electron transport chain, bypassing dysfunctional Complex I and Complex II. For conditions where mitochondrial dysfunction is upstream of neurodegeneration, that’s a genuinely useful probe mechanism, not a hand-wavy “supports mitochondria” claim. The Gonzalez-Lima group at UT Austin has published the most credible low-dose cognitive work, documenting improvements in rodent models of TBI, aging, fear extinction, and memory consolidation. The compound also appears to inhibit tau aggregation through a separate pathway, which is what pulled it into the Alzheimer’s space as a therapeutic candidate and gave it a second mechanistic identity worth tracking independently.
Dose-dependence here is important and a bit tricky to work around experimentally. Low-dose experiments need to be precisely calibrated. The blue staining effect on tissues and excreta is cosmetically obvious and can unmask participant blinding in clinical trials, a methodological headache that’s shown up more than once in the published discussion sections.
On the clinical side: the TauRx program used leucomethylthioninium, a reduced form, in phase 2 and phase 3 Alzheimer’s trials. Phase 2 signal was real and drew serious attention. Phase 3 confirmation was inconsistent. That outcome puts methylene blue in a familiar position: multi-lab preclinical is solid, small-N human cognitive signal exists but is modest, and replication is still genuinely in progress across several independent groups.
What we actually like here is the bench utility. Methylene blue is cheap, readily sourced at pharmaceutical grade, and provides a clean pharmacological tool for probing mitochondrial redox biology. If you’re building experiments around mitochondrial dysfunction in neurodegeneration, this belongs in the toolkit. We don’t think it’s a frontier compound, and we don’t think the cognitive signal is anywhere near settled. But it earns its place as a niche probe with a real mechanistic story and a well-characterized profile that makes it genuinely useful as a research instrument.